scholarly journals Diagnostic Ionizing Radiation Exposure in a Population-Based Cohort of Patients with Inflammatory Bowel Disease

2008 ◽  
Vol 103 (8) ◽  
pp. 2015-2022 ◽  
Author(s):  
Joanna M. Peloquin ◽  
Darrell S. Pardi ◽  
William J. Sandborn ◽  
Joel G. Fletcher ◽  
Cynthia H. McCollough ◽  
...  
2015 ◽  
Vol 16 (2) ◽  
pp. 83-89 ◽  
Author(s):  
Camila Estay ◽  
Daniela Simian ◽  
Jaime Lubascher ◽  
Carolina Figueroa ◽  
Andrés O'Brien ◽  
...  

2019 ◽  
Vol 26 (6) ◽  
pp. 898-906
Author(s):  
Geoffrey C Nguyen ◽  
Daniel Low ◽  
Rachel Y Chong ◽  
Christina Diong ◽  
Tanya Chawla

Abstract Background Abdominal imaging is important in managing inflammatory bowel disease (IBD). We characterized utilization of imaging and exposure to ionizing radiation. Methods We enumerated abdominal diagnostic imaging in a population-based cohort of IBD patients between 1994 and 2016. Trends in utilization of abdominal computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound were characterized. Cumulative doses of ionizing radiation were compared between IBD patients and non-IBD controls and between Crohn’s disease (CD) and ulcerative colitis (UC) patients. Regression models were constructed to assess predictors of high ionizing radiation exposure. Results There were 72,933 incident cases of IBD. During the first 5 years of diagnosis, IBD patients were exposed to nearly 6-fold higher exposure to cumulative ionizing radiation attributable to abdominal imaging compared with non-IBD controls (18.6 mSv vs 2.9 mSv). Cumulative ionizing radiation exposure was higher in CD than UC (26.0 mSv vs 12.0 mSv; P < 0.001). Crohn’s disease patients were more than twice as likely as UC patients to exceed 50 mSv (15.6% vs 6.2%; P < 0.001) and 100 mSV (5.0% vs 2.1%; P < 0.001). There was geographic variation in ionizing radiation exposure, and individuals of lower income were more likely to have high exposure. Utilization of abdominal MRI has increased substantially, peaking between 2007 and 2012 and increasing annually at 34%, which coincided with an annual 2% decline in the use of abdominal CT. Conclusions Crohn’s disease patients are at highest risk for high exposure to ionizing radiation, with a subgroup receiving potentially harmful levels. Increasing utilization and access to abdominal MRI may alleviate exposure.


2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Patrick D. Mc Laughlin ◽  
Owen J. O’Connor ◽  
Siobhán B. O’Neill ◽  
Fergus Shanahan ◽  
Michael M. Maher

Patient awareness and concern regarding the potential health risks from ionizing radiation have peaked recently (Coakley et al., 2011) following widespread press and media coverage of the projected cancer risks from the increasing use of computed tomography (CT) (Berrington et al., 2007). The typical young and educated patient with inflammatory bowel disease (IBD) may in particular be conscious of his/her exposure to ionising radiation as a result of diagnostic imaging. Cumulative effective doses (CEDs) in patients with IBD have been reported as being high and are rising, primarily due to the more widespread and repeated use of CT (Desmond et al., 2008). Radiologists, technologists, and referring physicians have a responsibility to firstly counsel their patients accurately regarding the actual risks of ionizing radiation exposure; secondly to limit the use of those imaging modalities which involve ionising radiation to clinical situations where they are likely to change management; thirdly to ensure that a diagnostic quality imaging examination is acquired with lowest possible radiation exposure. In this paper, we synopsize available evidence related to radiation exposure and risk and we report advances in low-dose CT technology and examine the role for alternative imaging modalities such as ultrasonography or magnetic resonance imaging which avoid radiation exposure.


2009 ◽  
Vol 104 (11) ◽  
pp. 2816-2823 ◽  
Author(s):  
Lena Palmer ◽  
Hans Herfarth ◽  
Carol Q Porter ◽  
Lynn A Fordham ◽  
Robert S Sandler ◽  
...  

2006 ◽  
Vol 101 ◽  
pp. S448-S449 ◽  
Author(s):  
Joanna M. Peloquin ◽  
Darrell S. Pardi ◽  
William J. Sandborn ◽  
Joel G. Fletcher ◽  
Cynthia H. McCollough ◽  
...  

2019 ◽  
Vol 25 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Clara Yzet ◽  
Stacy S. Tse ◽  
Maia Kayal ◽  
Robert Hirten ◽  
Jean-Frédéric Colombel

The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.


Sign in / Sign up

Export Citation Format

Share Document